Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Harvard Business School
Colorcon
Medtronic
Boehringer Ingelheim

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,063,927

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,063,927 protect, and when does it expire?

Patent 6,063,927 protects PAXIL and is included in one NDA.

Protection for PAXIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and fifty-seven patent family members in thirty-eight countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,063,927
Title: Paroxetine derivatives
Abstract:Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.
Inventor(s): Craig; Andrew Simon (Kent, GB), Jones; Alan David (Kent, GB), O'Keeffe; Deirdre (Surrey, GB), Ward; Neal (East Sussex, GB)
Assignee: SmithKline Beecham plc (Brentford, GB)
Application Number:09/299,060
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,063,927
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 6,063,927

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-001 Oct 9, 1998 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-002 Oct 9, 1998 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-003 Oct 9, 1998 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-004 Oct 9, 1998 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,063,927

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9814316Jul 02, 1998
United Kingdom9821732Oct 06, 1998
United Kingdom9902935Feb 10, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Harvard Business School
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.